DOP2018000001A - Moléculas de fusión - Google Patents

Moléculas de fusión

Info

Publication number
DOP2018000001A
DOP2018000001A DO2018000001A DO2018000001A DOP2018000001A DO P2018000001 A DOP2018000001 A DO P2018000001A DO 2018000001 A DO2018000001 A DO 2018000001A DO 2018000001 A DO2018000001 A DO 2018000001A DO P2018000001 A DOP2018000001 A DO P2018000001A
Authority
DO
Dominican Republic
Prior art keywords
fusion molecules
aeruginosa
present
relates
well
Prior art date
Application number
DO2018000001A
Other languages
English (en)
Inventor
Fraisse Laurent
Kruip Jochen
Lange Christian
Corvey Carsten
Stump Heike
Calandra Bernhard
Rey Astrid
Mourez Michael
Rothe Christine
Allersdorfer Andrea
Hinner Marlon
Lunde Bradley
Hülsmeyer Martin
Wiedenmann Alexander
Focken Ingo
Rat Dorothea
Stuedemann Thomas
Rasser Hans-Falk
Schaefer Juergen
Jensen Kristian
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2018000001A publication Critical patent/DOP2018000001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

La presente invención se refiere a moléculas de fusión que tienen especificidad de unión para pioverdina tipo I, II y III y pioquelina y pueden usarse en varias aplicaciones, incluyendo aplicaciones de diagnóstico y/o terapéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa y/o para prevenir o tratar una infección por biopelícula de P. aeruginosa así como enfermedades o trastornos asociados con una infección por biopelícula de P. aeruginosa. La presente invención también se refiere a métodos para producir las moléculas de fusión descritas en la presente memoria así como a composiciones y kits que comprenden dichas moléculas de fusión. La presente invención se refiere además a moléculas de ácido nucleico que codifican las moléculas de fusión descritas en la presente memoria. (fig.10)
DO2018000001A 2015-07-07 2018-01-03 Moléculas de fusión DOP2018000001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (en) 2015-07-07 2015-07-07 Fusion molecules

Publications (1)

Publication Number Publication Date
DOP2018000001A true DOP2018000001A (es) 2018-05-15

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000001A DOP2018000001A (es) 2015-07-07 2018-01-03 Moléculas de fusión

Country Status (26)

Country Link
US (2) US10316071B2 (es)
EP (2) EP3115371A1 (es)
JP (1) JP2018524003A (es)
KR (1) KR20180026755A (es)
CN (1) CN107849106A (es)
AR (1) AR105257A1 (es)
AU (1) AU2016289839A1 (es)
BR (1) BR112018000155A2 (es)
CA (1) CA2991298A1 (es)
CL (1) CL2018000015A1 (es)
CO (1) CO2018001188A2 (es)
CR (1) CR20180079A (es)
DO (1) DOP2018000001A (es)
EA (1) EA201890234A1 (es)
EC (1) ECSP18008488A (es)
HK (1) HK1249110A1 (es)
IL (1) IL256694A (es)
MA (1) MA42006A1 (es)
MX (1) MX2018000206A (es)
PE (1) PE20180490A1 (es)
PH (1) PH12018500058A1 (es)
TN (1) TN2017000547A1 (es)
TW (1) TW201716435A (es)
UY (1) UY36772A (es)
WO (1) WO2017005763A1 (es)
ZA (1) ZA201708754B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
AU2009264214B2 (en) * 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
EP3660510A3 (en) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP3441400B1 (en) * 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
MX2018000206A (es) 2018-02-26
HK1249110A1 (zh) 2018-10-26
CR20180079A (es) 2018-04-24
CO2018001188A2 (es) 2018-05-10
EP3115371A1 (en) 2017-01-11
UY36772A (es) 2017-01-31
BR112018000155A2 (pt) 2018-09-11
US20190382455A1 (en) 2019-12-19
EP3319986A1 (en) 2018-05-16
EA201890234A1 (ru) 2018-06-29
TW201716435A (zh) 2017-05-16
IL256694A (en) 2018-03-29
US20170029477A1 (en) 2017-02-02
CA2991298A1 (en) 2017-01-12
JP2018524003A (ja) 2018-08-30
PH12018500058A1 (en) 2018-07-09
TN2017000547A1 (en) 2019-04-12
ZA201708754B (en) 2018-11-28
US10947284B2 (en) 2021-03-16
PE20180490A1 (es) 2018-03-07
MA42006A1 (fr) 2018-09-28
WO2017005763A1 (en) 2017-01-12
CL2018000015A1 (es) 2018-07-13
US10316071B2 (en) 2019-06-11
AR105257A1 (es) 2017-09-20
ECSP18008488A (es) 2018-04-30
CN107849106A (zh) 2018-03-27
KR20180026755A (ko) 2018-03-13
AU2016289839A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CL2017002650A1 (es) Compuestos novedosos
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112018006636A2 (pt) composições de oligonucleotídeo e métodos destas
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
CL2016002971A1 (es) Combinación.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
EA201591761A1 (ru) Композиции на основе наночастиц
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015029970A2 (pt) inibidores de cinase
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
DOP2018000001A (es) Moléculas de fusión
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
BR112018014771A2 (pt) composição compreendendo extrato de proteoglicanos de algas e seu uso
TH182687B (th) โมเลกุลฟิวชัน
UY37032A (es) Compuestos de heteroarilbenzimidazol